Want to see IN:SUPRIYA full AI Analyst Report?
SUPRIYA Stock Chart & Stats
₹751.00
-₹18.10(-2.41%)
At close: 4:00 PM EST
₹751.00
-₹18.10(-2.41%)
Day’s Range― - ―
52-Week Range₹545.65 - ₹1,085.50
Previous CloseN/A
Volume168.68K
Average Volume (3M)18.01K
Market Cap
₹63.69B
Enterprise Value₹57.66K
Total Cash (Recent Filing)₹788.67M
Total Debt (Recent Filing)₹54.35M
Price to Earnings (P/E)31.7
Beta1.24
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)25.98
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.9
Revenue Forecast (FY)₹9.94B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion indicates increasing API demand and improving market reach. Continued growth across recent years can support operating scale, customer penetration, and internal funding for future capacity or product development.
Conservative Balance SheetVery low leverage reduces interest burden and refinancing risk, giving Supriya greater resilience during industry or pricing pressure. A stronger equity base also provides flexibility to fund expansion without relying heavily on external debt.
Improving Operating Cash FlowStronger operating cash flow improves earnings quality and supports internally funded investment. The recent free-cash-flow rebound suggests the business can increasingly convert profits into liquidity, strengthening financial flexibility over the next several quarters.
Bears Say
Historical Free-Cash-Flow VolatilityThe prior period of negative free cash flow indicates that investment requirements or working-capital movements can materially reduce cash conversion. This creates uncertainty around the consistency of internally generated funds despite the latest improvement.
Margin And Earnings VolatilityVariability in profitability suggests results remain sensitive to API product mix, pricing conditions, and input costs. If these pressures persist, revenue growth may not translate proportionally into operating profit or earnings.
Normalizing ReturnsModerating returns on equity may indicate that incremental capital is producing lower profitability than in earlier periods. As the asset and equity base expands, maintaining efficient capital deployment will be important for sustaining shareholder returns.
Supriya Lifescience Limited News
SUPRIYA FAQ
What was Supriya Lifescience Limited’s price range in the past 12 months?
Supriya Lifescience Limited lowest stock price was ₹545.65 and its highest was ₹1085.50 in the past 12 months.
What is Supriya Lifescience Limited’s market cap?
Supriya Lifescience Limited’s market cap is ₹63.69B.
When is Supriya Lifescience Limited’s upcoming earnings report date?
Supriya Lifescience Limited’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Supriya Lifescience Limited’s earnings last quarter?
Supriya Lifescience Limited released its earnings results on Aug 13, 2026. The company reported ₹3 earnings per share for the quarter, missing the consensus estimate of ₹9.3 by -₹6.3.
Is Supriya Lifescience Limited overvalued?
According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued.
Does Supriya Lifescience Limited pay dividends?
Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here
What is Supriya Lifescience Limited’s EPS estimate?
Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Supriya Lifescience Limited have?
Supriya Lifescience Limited has 80,482,800 shares outstanding.
What happened to Supriya Lifescience Limited’s price movement after its last earnings report?
Supriya Lifescience Limited reported an EPS of ₹3 in its last earnings report, missing expectations of ₹9.3. Following the earnings report the stock price went down -2.183%.
Which hedge fund is a major shareholder of Supriya Lifescience Limited?
Currently, no hedge funds are holding shares in IN:SUPRIYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Technical Analysis
Blue Jet Healthcare Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Zota Health Care Ltd.
―
OneSource Specialty Pharma Limited
―